Etalon Secures $18 Million ‘Series A’ Funding in Partnership with Teton Ridge

provides real, in-depth, ‘whole picture’ insight with actionable results; not just a surface view. Combining this technology with openly collaborative everyday horse owner knowhow has put a whole new spin on ‘crowdsourcing’. The science alone is potent, but this combination is especially powerful.”

Using internal expertise alongside strong collaboration with veterinarians, top equestrians, and the everyday horse owner, rider, and enthusiast, Etalon has already developed industry-leading genetic discovery tools and an affordable, comprehensive set of user-friendly applications. These tools and applications, like Build-a-Horse, allow horse owners to understand the health, disposition, and strengths of their horse(s), turning once-complex genetic analysis into easyto-understand, usable, and actionable data. Building on these concepts and technologies, Etalon is also developing genetic therapies for animals with the goal of reversing human-induced damage such as inbreeding and disease propagation resulting from fashionable breeding. These genetic therapies, advancements, and innovations will have positive implications for the horse as well as for humans and other mammals.

“Teton Ridge has invested in Etalon because it aligns with our mission of innovation within the equine industry,” said Thomas Tull, founder and chairman of Teton Ridge. “The science behind Etalon is an unprecedented advancement in equine genetics, using this technology and a proprietary platform to maximize suitability and ultimate performance.”